Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation

BackgroundThis study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China.MethodsThis study employed the Building, Relating, Assessing, an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jiali Qin, Man Tang, Xiaomei Wang, Lizheng Shi, Hui Shao, Vivian Fonseca, Xiaoyan You, Xianying Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-05-01
Colecção:	Frontiers in Public Health
Assuntos:	BRAVO model cost-effectiveness analysis IDegAsp IGlarLixi type 2 diabetes
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fpubh.2026.1787562/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!